Publication: Omaveloxolone and TX63682 Are Hepatoprotective in the STAM Mouse Model of NASH

This preclinical study evaluated the effects of omaveloxolone and TX63682, a closely related structural analog, in the STAM mouse model of nonalcoholic steatohepatitis (NASH), a progressive form of liver disease.

Publication: TSUBAKI, a Study of Bardoxolone Methyl in Patients with Diabetic CKD

TSUBAKI was a Phase 2, randomized, multicenter, double-blind, placebo-controlled study of bardoxolone methyl in patients with type 2 diabetes and stage 3-4 chronic kidney disease. The primary efficacy endpoint was change from baseline in GFR measured by inulin clearance at week 16.

Publication: Bardoxolone Methyl Analog Attenuates Proteinuria-Induced Tubular Damage by Modulating Mitochondrial Function

The effects of dihydro‐CDDO‐trifluoroethyl amide (dh404), a rodent‐tolerable bardoxolone methyl analog, on the tubulointerstitium, were tested in an Institute of Cancer Research‐derived glomerulonephritis (ICGN) mouse model of kidney disease. The effect of dh404 on mitochondrial function, was assessed using human proximal tubular cells in vitro.

Publication: Effect of Bardoxolone Methyl on the Urine Albumin-To-Creatinine Ratio in Patients With Type 2 Diabetes and Stage 4 Chronic Kidney Disease

Post-hoc analyses to characterize the relationship between the urine albumin-to-creatinine ratio and estimated glomerular filtration rate in response to bardoxolone methyl treatment in BEACON, a Phase 3 placebo-controlled, randomized, double-blind, parallel-group, international, multicenter trial of bardoxolone methyl in 2,185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.

Publication: Effects of Bardoxolone Methyl on Body Weight, Waist Circumference and Glycemic Control in Obese Patients with T2DM and Stage 4 Chronic Kidney Disease

Post-hoc analyses to characterize changes in body weight in response to bardoxolone methyl treatment in BEACON, a Phase 3 placebo-controlled, randomized, double-blind, parallel-group, international, multicenter trial of bardoxolone methyl in 2,185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.

Publication: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study

Post-hoc analyses to characterize changes in kidney function in response to bardoxolone methyl treatment in BEACON, a Phase 3 placebo-controlled, randomized, double-blind, parallel-group, international, multicenter trial of bardoxolone methyl in 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.

Publication: Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney

A preclinical investigation on the role of megalin, a protein involved in the tubular reabsorption of albumin and lipid-bound proteins, in changes in albuminuria in animals treated with bardoxolone methyl.